Identification

Name
Zonisamide
Accession Number
DB00909  (APRD00004)
Type
Small Molecule
Groups
Approved, Investigational
Description

Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.

Structure
Thumb
Synonyms
  • 1,2-Benzisoxazole-3-methanesulfonamide
  • 3-(Sulfamoylmethyl)-1,2-benzisoxazole
  • Benzo[d]isoxazol-3-yl-methanesulfonamide
  • Zonisamida
  • Zonisamidum
External IDs
AD-810 / CI-912 / PD-110843
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZonegranCapsule25 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule100 mg/1OralEisai Limited2000-03-27Not applicableUs
ZonegranCapsule50 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranTablet, orally disintegrating25 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranTablet, orally disintegrating100 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule100 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranTablet, orally disintegrating50 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule50 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule100 mg/1OralConcordia Pharmaceuticals, Inc2000-03-27Not applicableUs
ZonegranCapsule100 mgOralEisai Limited2005-03-10Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZonisamideCapsule100 mg/1OralCamber Pharmaceuticals2012-02-21Not applicableUs
ZonisamideCapsule25 mg/1OralApotex Corporation2005-12-22Not applicableUs
ZonisamideCapsule50 mg/1OralWockhardt2006-07-27Not applicableUs
ZonisamideCapsule100 mg/1OralCipla Limited2016-07-13Not applicableUs
ZonisamideCapsule50 mg/1OralDr Reddy's Laboratories2005-12-22Not applicableUs
ZonisamideCapsule100 mg/1OralEon Labs, Inc.2005-12-22Not applicableUs
ZonisamideCapsule50 mg/1OralBlue Point Laboratories2014-03-13Not applicableUs
ZonisamideCapsule100 mg/1OralAidarex Pharmaceuticals LLC2016-07-13Not applicableUs
ZonisamideCapsule50 mg/1OralRebel Distributors2006-03-17Not applicableUs62756 0259 02 nlmimage10 f6387b03
ZonisamideCapsule50 mg/1OralDirectrx2015-01-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZonisamideCapsule100 mg/1OralNu Care Pharmaceuticals,inc.2006-01-30Not applicableUs
ZonisamideCapsule100 mg/1OralDirectrx2017-11-10Not applicableUs
International/Other Brands
Exceglan / Excegram / Excegran
Categories
UNII
459384H98V
CAS number
68291-97-4
Weight
Average: 212.226
Monoisotopic: 212.025562822
Chemical Formula
C8H8N2O3S
InChI Key
UBQNRHZMVUUOMG-UHFFFAOYSA-N
InChI
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
IUPAC Name
1,2-benzoxazol-3-ylmethanesulfonamide
SMILES
NS(=O)(=O)CC1=NOC2=CC=CC=C12

Pharmacology

Indication

For use as adjunctive treatment of partial seizures in adults with epilepsy.

Structured Indications
Pharmacodynamics

Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium and calcium channels, which leads to the suppression of neuronal hypersynchronization (i.e. convulsions). Sonisamide has also been found to potentiate dopaminergic and serotonergic neurotransmission but does not appear to potentiate syanptic activity by GABA (gamma amino butyric acid).

Mechanism of action

Zonisamide binds to sodium channels and voltage sensitive calcium channels, which suppresses neuronal depolarization and hypersynchronization. Zonisamide also inhibits carbonic anhydrase to a weaker extent, but such an effect is not thought to contribute substantially to the drug's anticonvulsant activity.

TargetActionsOrganism
ASodium channel protein type 1 subunit alpha
inhibitor
Human
ASodium channel protein type 2 subunit alpha
inhibitor
Human
ASodium channel protein type 3 subunit alpha
inhibitor
Human
ASodium channel protein type 4 subunit alpha
inhibitor
Human
ASodium channel protein type 5 subunit alpha
inhibitor
Human
ASodium channel protein type 9 subunit alpha
inhibitor
Human
ASodium channel protein type 11 subunit alpha
inhibitor
Human
ASodium channel subunit beta-1
inhibitor
Human
ASodium channel subunit beta-2
inhibitor
Human
ASodium channel subunit beta-3
inhibitor
Human
ASodium channel subunit beta-4
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1I
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
UCarbonic anhydrase 4
inhibitor
Human
UCarbonic anhydrase 5A, mitochondrial
inhibitor
Human
UCarbonic anhydrase 5B, mitochondrial
inhibitor
Human
UCarbonic anhydrase 6
inhibitor
Human
UCarbonic anhydrase 7
inhibitor
Human
UCarbonic anhydrase-related protein
inhibitor
Human
UCarbonic anhydrase 9
inhibitor
Human
UCarbonic anhydrase-related protein 10
inhibitor
Human
UCarbonic anhydrase-related protein 11
inhibitor
Human
UCarbonic anhydrase 12
inhibitor
Human
UCarbonic anhydrase 13
inhibitor
Human
UCarbonic anhydrase 14
inhibitor
Human
UAmine oxidase [flavin-containing] B
inhibitor
Human
UAmine oxidase [flavin-containing] A
inhibitor
Human
Absorption

Variable, yet relatively rapid rate of absorption with a time to peak concentration of 2.8-3.9 hours. Food has no effect on the bioavailability of zonisamide.

Volume of distribution
  • 1.45 L/kg
Protein binding

40% (at concentrations of 1.0-7.0 µg/mL)

Metabolism

Primarily hepatic through cytochrome P450 isoenzyme 3A4 (CYP3A4). Undergoes acetylation and reduction, forming N-acetyl zonisamide, and the open-ring metabolite 2–sulfamoylacetyl phenol, respectively.

Route of elimination

Zonisamide is excreted primarily in urine as parent drug and as the glucuronide of a metabolite.

Half life

63 hours

Clearance
  • 0.30 - 0.35 mL/min/kg [patients not receiving enzyme-inducing antiepilepsy drugs (AEDs)]
  • 0.35 - 0.5 mL/min/kg [Concomitant administration of phenytoin and carbamazepine]
Toxicity

Symptoms of overdose include diminished breathing, loss of consciousness, low blood pressure, and slow heartbeat.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Zonisamide.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zonisamide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zonisamide.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Zonisamide.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zonisamide.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Zonisamide.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Zonisamide.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Zonisamide.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Zonisamide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Zonisamide.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zonisamide.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Zonisamide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zonisamide.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zonisamide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zonisamide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zonisamide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Zonisamide.Experimental
AprepitantThe serum concentration of Zonisamide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zonisamide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Zonisamide.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Zonisamide.Approved
AtazanavirThe metabolism of Zonisamide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Zonisamide can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Zonisamide.Investigational, Vet Approved
AzelastineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Zonisamide.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Zonisamide.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Zonisamide.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zonisamide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Zonisamide.Approved
BoceprevirThe metabolism of Zonisamide can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Zonisamide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Zonisamide can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zonisamide.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Zonisamide.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Zonisamide.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zonisamide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Zonisamide.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zonisamide.Approved, Investigational
BuprenorphineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zonisamide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zonisamide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Zonisamide.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Zonisamide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Zonisamide.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Zonisamide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zonisamide.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Zonisamide.Investigational
CarbamazepineThe metabolism of Zonisamide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zonisamide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Zonisamide.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zonisamide.Approved
CeritinibThe serum concentration of Zonisamide can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zonisamide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zonisamide.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zonisamide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Zonisamide.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zonisamide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zonisamide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zonisamide.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zonisamide.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Zonisamide.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zonisamide.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Zonisamide is combined with Citalopram.Approved
ClarithromycinThe metabolism of Zonisamide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Zonisamide can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Zonisamide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Zonisamide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Zonisamide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Zonisamide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Zonisamide.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zonisamide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Zonisamide.Experimental
ClotrimazoleThe metabolism of Zonisamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Zonisamide.Approved
CobicistatThe metabolism of Zonisamide can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zonisamide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zonisamide.Approved, Illicit
ConivaptanThe serum concentration of Zonisamide can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Zonisamide can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zonisamide.Approved
CyclosporineThe metabolism of Zonisamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Zonisamide.Approved
DabrafenibThe serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zonisamide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Zonisamide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Zonisamide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Zonisamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Zonisamide can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Zonisamide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Zonisamide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Zonisamide.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zonisamide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Zonisamide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zonisamide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Zonisamide.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zonisamide.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Zonisamide.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zonisamide.Approved, Illicit
DihydroergotamineThe metabolism of Zonisamide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zonisamide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zonisamide.Experimental, Illicit
DiltiazemThe metabolism of Zonisamide can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zonisamide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zonisamide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Zonisamide.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Zonisamide.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Doxepin.Approved
DoxycyclineThe metabolism of Zonisamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Zonisamide.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Illicit
DronedaroneThe metabolism of Zonisamide can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Zonisamide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zonisamide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Zonisamide.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Zonisamide.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Zonisamide.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Zonisamide.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zonisamide.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Zonisamide.Approved, Investigational
EnzalutamideThe serum concentration of Zonisamide can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Zonisamide can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zonisamide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zonisamide.Approved
EthanolZonisamide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zonisamide.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zonisamide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zonisamide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zonisamide.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Zonisamide.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zonisamide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zonisamide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Zonisamide.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Zonisamide.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Zonisamide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zonisamide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Zonisamide.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zonisamide.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zonisamide.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Zonisamide.Experimental
FluconazoleThe metabolism of Zonisamide can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zonisamide.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zonisamide.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zonisamide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zonisamide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zonisamide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zonisamide.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Zonisamide.Approved
FluvoxamineThe metabolism of Zonisamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Zonisamide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zonisamide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Zonisamide can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Zonisamide.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Zonisamide can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zonisamide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Zonisamide.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Zonisamide.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Zonisamide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Zonisamide.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zonisamide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Zonisamide.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Zonisamide.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zonisamide.Approved
HydrocodoneZonisamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iloperidone.Approved
ImatinibThe metabolism of Zonisamide can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Zonisamide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Zonisamide can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Zonisamide.Investigational
IsavuconazoniumThe metabolism of Zonisamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Zonisamide.Approved, Vet Approved
IsradipineThe metabolism of Zonisamide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Zonisamide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Zonisamide can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zonisamide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zonisamide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Zonisamide.Approved, Investigational
KetoconazoleThe metabolism of Zonisamide can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zonisamide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Zonisamide.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zonisamide.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zonisamide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zonisamide.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Zonisamide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Zonisamide.Illicit
LopinavirThe metabolism of Zonisamide can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Zonisamide.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Zonisamide.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zonisamide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Zonisamide.Approved
LovastatinThe metabolism of Zonisamide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zonisamide.Approved
LuliconazoleThe serum concentration of Zonisamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Zonisamide can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Zonisamide.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Zonisamide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Zonisamide.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Zonisamide.Vet Approved
MefloquineThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Zonisamide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Zonisamide.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zonisamide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Zonisamide.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zonisamide.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Zonisamide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Zonisamide.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zonisamide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Zonisamide.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zonisamide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zonisamide.Approved
MethotrimeprazineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zonisamide.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Zonisamide.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zonisamide.Approved
MetyrosineZonisamide may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zonisamide.Approved, Illicit
MifepristoneThe serum concentration of Zonisamide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Zonisamide is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
MirtazapineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Zonisamide can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Zonisamide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zonisamide.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zonisamide.Approved
NefazodoneThe metabolism of Zonisamide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Zonisamide can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Zonisamide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Zonisamide can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Zonisamide can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zonisamide.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Zonisamide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Zonisamide.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Zonisamide.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zonisamide.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zonisamide.Approved, Investigational
OlaparibThe metabolism of Zonisamide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zonisamide.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zonisamide.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Zonisamide.Approved, Illicit
OrlistatThe serum concentration of Zonisamide can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Zonisamide.Investigational
OsimertinibThe serum concentration of Zonisamide can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zonisamide.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Zonisamide.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zonisamide.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zonisamide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zonisamide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zonisamide.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Zonisamide can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zonisamide.Approved
ParaldehydeZonisamide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Zonisamide.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide.Approved, Vet Approved
PentobarbitalThe metabolism of Zonisamide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Zonisamide.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Zonisamide.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zonisamide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zonisamide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Zonisamide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Zonisamide.Experimental
PhenobarbitalThe serum concentration of Zonisamide can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Zonisamide.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Zonisamide.Approved
PhenytoinThe serum concentration of Zonisamide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Zonisamide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zonisamide.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Zonisamide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Zonisamide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleZonisamide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Zonisamide.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Zonisamide.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zonisamide.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Zonisamide.Approved
PrimidoneThe metabolism of Zonisamide can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Zonisamide.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Zonisamide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Zonisamide.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zonisamide.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Zonisamide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Zonisamide.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Zonisamide.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Zonisamide.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zonisamide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zonisamide.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Zonisamide.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Zonisamide.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Zonisamide can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zonisamide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zonisamide.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zonisamide.Approved, Investigational
RifabutinThe metabolism of Zonisamide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Zonisamide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Zonisamide can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zonisamide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Zonisamide.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Zonisamide.Vet Approved
RopiniroleZonisamide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zonisamide.Approved
RotigotineZonisamide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zonisamide.Approved
SaquinavirThe metabolism of Zonisamide can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zonisamide.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zonisamide.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Zonisamide.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Zonisamide.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zonisamide.Approved, Vet Approved
SildenafilThe metabolism of Zonisamide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Zonisamide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Zonisamide can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
St. John's WortThe serum concentration of Zonisamide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Zonisamide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.Approved, Investigational
SulfisoxazoleThe metabolism of Zonisamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zonisamide.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Zonisamide.Experimental
SuvorexantZonisamide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Zonisamide.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Zonisamide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Zonisamide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zonisamide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Zonisamide.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Zonisamide.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zonisamide.Investigational
ThalidomideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zonisamide.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Zonisamide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zonisamide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zonisamide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zonisamide.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Zonisamide.Approved, Investigational
TiclopidineThe metabolism of Zonisamide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Zonisamide.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Zonisamide.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zonisamide.Approved
TocilizumabThe serum concentration of Zonisamide can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zonisamide.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Zonisamide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zonisamide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zonisamide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zonisamide.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Zonisamide.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zonisamide.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Zonisamide.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Zonisamide.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zonisamide.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Zonisamide.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zonisamide.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zonisamide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zonisamide.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zonisamide.Approved, Investigational
VenlafaxineThe metabolism of Zonisamide can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Zonisamide.Experimental
VerapamilThe metabolism of Zonisamide can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Zonisamide.Experimental
VoriconazoleThe metabolism of Zonisamide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zonisamide.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Zonisamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Zonisamide.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zonisamide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Zonisamide can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Zonisamide.Vet Approved
ZolpidemZonisamide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Zonisamide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Zonisamide.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Tamar Nidam, "Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms." U.S. Patent US20030114682, issued June 19, 2003.

US20030114682
General References
  1. Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001 Dec;41(4):397-9. [PubMed:11755227]
  2. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003 Apr 9;289(14):1820-5. [PubMed:12684361]
  3. Hasegawa H: Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin. 2004 May;20(5):577-80. [PubMed:15140322]
  4. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  5. Ueda Y, Doi T, Tokumaru J, Willmore LJ: Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6. [PubMed:12941455]
  6. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  7. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  8. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  9. Peters DH, Sorkin EM: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May;45(5):760-87. [PubMed:7686468]
  10. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
External Links
Human Metabolome Database
HMDB15045
KEGG Drug
D00538
KEGG Compound
C07504
PubChem Compound
5734
PubChem Substance
46505278
ChemSpider
5532
BindingDB
10888
ChEBI
10127
ChEMBL
CHEMBL750
Therapeutic Targets Database
DAP000500
PharmGKB
PA451978
HET
ZON
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Zonisamide
ATC Codes
N03AX15 — Zonisamide
PDB Entries
3po7
FDA label
Download (124 KB)
MSDS
Download (58.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers2
1RecruitingTreatmentAlcohol Use Disorder (AUD)1
1, 2CompletedNot AvailableDependence, Cocaine1
1, 2Unknown StatusTreatmentNicotine Dependence1
1, 2WithdrawnPreventionNoise Induced Hearing Loss1
2CompletedPreventionMigrainous Headache1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentBMI >30 kg/m2 / Obstructive Sleep Apnea (OSA) / Sleep Apnea Syndrome1
2CompletedTreatmentTremor, Essential1
2RecruitingTreatmentAlcohol Dependence / Post-Traumatic Stress Disorder (PTSD)1
2TerminatedTreatmentAlcohol Abuse / Alcohol Dependence / Alcoholism1
2TerminatedTreatmentAlcohol Use Disorders (AUD) / Bipolar Disorder (BD)1
2, 3Unknown StatusTreatmentParkinson's Disease (PD)1
3CompletedPreventionSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedPreventionWeight gain therapy1
3CompletedTreatmentBinge Eating Disorder Associated With Obesity1
3CompletedTreatmentEpilepsies3
3CompletedTreatmentEpilepsy, Complex Partial1
3CompletedTreatmentEpilepsy; Paediatric Partial Onset Seizures1
3CompletedTreatmentMyoclonus Dystonia1
3CompletedTreatmentPartial onset seizure Epilepsy2
3Not Yet RecruitingTreatmentAlcohol Dependence1
3RecruitingTreatmentAlcohol Use Disorder (AUD)1
3TerminatedTreatmentEpilepsies2
4CompletedNot AvailablePartial, Generalized and Combined Seizures1
4CompletedTreatmentAlcohol Abuse / Alcohol Dependence / Alcoholism1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentEpilepsies6
4CompletedTreatmentEpilepsy, Localization Related1
4Enrolling by InvitationTreatmentEpilepsies1
4RecruitingTreatmentDyskinesias / Parkinson's Disease (PD) / Parkinsonism1
4RecruitingTreatmentEpilepsies1
4TerminatedTreatmentBipolar Disorder (BD)1
4TerminatedTreatmentEpilepsies1
4WithdrawnTreatmentFibromyalgia / Migraines1
Not AvailableCompletedNot AvailableAlcoholism1
Not AvailableCompletedNot AvailableEpilepsies1
Not AvailableCompletedTreatmentBMI >30 kg/m21
Not AvailableTerminatedTreatmentTremor, Essential1
Not AvailableUnknown StatusNot AvailablePartial onset seizure Epilepsy1
Not AvailableUnknown StatusHealth Services ResearchMigraines1

Pharmacoeconomics

Manufacturers
  • Eisai inc
  • Alphapharm party ltd
  • Apotex inc etobicoke site
  • Banner pharmacaps inc
  • Barr laboratories inc
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Glenmark generics inc usa
  • Invagen pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Wockhardt ltd
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tablet, orally disintegratingOral100 mg
Tablet, orally disintegratingOral25 mg
Tablet, orally disintegratingOral300 mg
Tablet, orally disintegratingOral50 mg
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral100 mg
CapsuleOral25 mg
CapsuleOral50 mg
Prices
Unit descriptionCostUnit
Zonegran 100 mg capsule3.33USD capsule
Zonisamide 100 mg capsule2.24USD capsule
Zonegran 50 mg capsule1.22USD capsule
Zonisamide 50 mg capsule1.12USD capsule
Zonegran 25 mg capsule0.94USD capsule
Zonisamide 25 mg capsule0.56USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)161-163 °CNot Available
water solubility0.8 mg/mLNot Available
logP0.5Not Available
pKa10.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.09 mg/mLALOGPS
logP0.67ALOGPS
logP0.11ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)9.84ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.19 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity50.3 m3·mol-1ChemAxon
Polarizability19.48 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9755
Caco-2 permeable-0.6385
P-glycoprotein substrateNon-substrate0.8681
P-glycoprotein inhibitor INon-inhibitor0.9258
P-glycoprotein inhibitor IINon-inhibitor0.9513
Renal organic cation transporterNon-inhibitor0.8463
CYP450 2C9 substrateNon-substrate0.8828
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5419
CYP450 1A2 substrateNon-inhibitor0.5762
CYP450 2C9 inhibitorNon-inhibitor0.697
CYP450 2D6 inhibitorNon-inhibitor0.8081
CYP450 2C19 inhibitorNon-inhibitor0.6007
CYP450 3A4 inhibitorNon-inhibitor0.8141
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7315
Ames testNon AMES toxic0.6276
CarcinogenicityNon-carcinogens0.7572
BiodegradationNot ready biodegradable0.9708
Rat acute toxicity2.0592 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8549
hERG inhibition (predictor II)Non-inhibitor0.8937
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0900000000-c05ae650c884adcaba5a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0900000000-477908537d156d43e3a9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0900000000-f537644668fbc9b2e02b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-1900000000-6359b9c8e68ec5477b26
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-3900000000-db3cf8881465259c48ca
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-6900000000-cd4c8b86f36ce38b3a49
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0930000000-a0dd3941aea211aeb201
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-88938a9c69a2d4daf36a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-2900000000-3440f1648bff05d21a31
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-5900000000-a727755cf1e18764e9d0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udj-9600000000-aa8a18a9ab17508f689d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udj-9200000000-41d7e769a93444ba3751
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0gx0-0940000000-22533c93dd06de52f6a8

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzisoxazoles. These are aromatic compounds containing a benzene ring fused to an isoxazole ring. Isoxazole is five-membered ring with three carbon atoms, and an oxygen atom next to a nitrogen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzisoxazoles
Sub Class
Not Available
Direct Parent
Benzisoxazoles
Alternative Parents
Organosulfonamides / Organic sulfonamides / Benzenoids / Isoxazoles / Heteroaromatic compounds / Aminosulfonyl compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Benzisoxazole / Organic sulfonic acid amide / Organosulfonic acid amide / Benzenoid / Azole / Isoxazole / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl / Aminosulfonyl compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, 1,2-benzoxazoles (CHEBI:10127)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN1A
Uniprot ID
P35498
Uniprot Name
Sodium channel protein type 1 subunit alpha
Molecular Weight
228969.49 Da
References
  1. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  2. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  3. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  4. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN2A
Uniprot ID
Q99250
Uniprot Name
Sodium channel protein type 2 subunit alpha
Molecular Weight
227972.64 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN3A
Uniprot ID
Q9NY46
Uniprot Name
Sodium channel protein type 3 subunit alpha
Molecular Weight
226291.905 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN4A
Uniprot ID
P35499
Uniprot Name
Sodium channel protein type 4 subunit alpha
Molecular Weight
208059.175 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN9A
Uniprot ID
Q15858
Uniprot Name
Sodium channel protein type 9 subunit alpha
Molecular Weight
226370.175 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN11A
Uniprot ID
Q9UI33
Uniprot Name
Sodium channel protein type 11 subunit alpha
Molecular Weight
204919.66 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in purkinje myocyte action potential
Specific Function
Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-1 can modulate multiple alpha subunit isoforms from brain, skele...
Gene Name
SCN1B
Uniprot ID
Q07699
Uniprot Name
Sodium channel subunit beta-1
Molecular Weight
24706.955 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in cardiac muscle cell action potential
Specific Function
Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-2 causes an increase in the plasma membrane surface area and in ...
Gene Name
SCN2B
Uniprot ID
O60939
Uniprot Name
Sodium channel subunit beta-2
Molecular Weight
24325.69 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in cardiac muscle cell action potential
Specific Function
Modulates channel gating kinetics. Causes unique persistent sodium currents. Inactivates the sodium channel opening more slowly than the subunit beta-1. Its association with neurofascin may target ...
Gene Name
SCN3B
Uniprot ID
Q9NY72
Uniprot Name
Sodium channel subunit beta-3
Molecular Weight
24702.08 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in cardiac muscle cell action potential
Specific Function
Modulates channel gating kinetics. Causes negative shifts in the voltage dependence of activation of certain alpha sodium channels, but does not affect the voltage dependence of inactivation. Modul...
Gene Name
SCN4B
Uniprot ID
Q8IWT1
Uniprot Name
Sodium channel subunit beta-4
Molecular Weight
24968.755 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  4. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  5. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  6. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  7. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  8. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  9. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  10. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  11. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  12. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  4. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  8. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  9. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  10. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  4. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  8. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  9. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  10. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
Details
15. Carbonic anhydrase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6. doi: 10.1080/14756360701507001 . [PubMed:18343915]
  4. Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung. 1993 Apr;43(4):416-8. [PubMed:8494570]
  5. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  6. Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. [PubMed:18162396]
  7. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  8. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
16. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6. doi: 10.1080/14756360701507001 . [PubMed:18343915]
  4. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  5. Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung. 1993 Apr;43(4):416-8. [PubMed:8494570]
  6. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  7. Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. [PubMed:18162396]
  8. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  9. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
17. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. [PubMed:18162396]
  5. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  6. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
18. Carbonic anhydrase 4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Low activity.
Gene Name
CA5A
Uniprot ID
P35218
Uniprot Name
Carbonic anhydrase 5A, mitochondrial
Molecular Weight
34750.21 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  4. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  5. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  6. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA5B
Uniprot ID
Q9Y2D0
Uniprot Name
Carbonic anhydrase 5B, mitochondrial
Molecular Weight
36433.43 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  4. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  5. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  6. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
21. Carbonic anhydrase 6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Its role in saliva is unknown.
Gene Name
CA6
Uniprot ID
P23280
Uniprot Name
Carbonic anhydrase 6
Molecular Weight
35366.615 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
22. Carbonic anhydrase 7
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA7
Uniprot ID
P43166
Uniprot Name
Carbonic anhydrase 7
Molecular Weight
29658.235 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Does not have a carbonic anhydrase catalytic activity.
Gene Name
CA8
Uniprot ID
P35219
Uniprot Name
Carbonic anhydrase-related protein
Molecular Weight
32972.915 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
24. Carbonic anhydrase 9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervic...
Gene Name
CA9
Uniprot ID
Q16790
Uniprot Name
Carbonic anhydrase 9
Molecular Weight
49697.36 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Not Available
Specific Function
Does not have a catalytic activity.
Gene Name
CA10
Uniprot ID
Q9NS85
Uniprot Name
Carbonic anhydrase-related protein 10
Molecular Weight
37562.655 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Not Available
Specific Function
Does not have a catalytic activity.
Gene Name
CA11
Uniprot ID
O75493
Uniprot Name
Carbonic anhydrase-related protein 11
Molecular Weight
36237.885 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
27. Carbonic anhydrase 12
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA12
Uniprot ID
O43570
Uniprot Name
Carbonic anhydrase 12
Molecular Weight
39450.615 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
28. Carbonic anhydrase 13
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA13
Uniprot ID
Q8N1Q1
Uniprot Name
Carbonic anhydrase 13
Molecular Weight
29442.895 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
29. Carbonic anhydrase 14
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA14
Uniprot ID
Q9ULX7
Uniprot Name
Carbonic anhydrase 14
Molecular Weight
37667.37 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  2. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  3. Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001 Dec;41(4):397-9. [PubMed:11755227]
  4. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. [PubMed:8991786]
  5. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  6. Okada M: [Effects of carbamazepine and zonisamide on dopaminergic system in rat striatum and hippocampus]. Nihon Shinkei Seishin Yakurigaku Zasshi. 1994 Oct;14(5):337-54. [PubMed:7856330]
  7. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. [PubMed:8991786]
  2. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M: Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol. 1993 Jul;44(1):216-21. [PubMed:8341274]
  2. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  3. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  4. Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M: Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83. [PubMed:9626925]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine dehydrogenase activity
Specific Function
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
Gene Name
AOX1
Uniprot ID
Q06278
Uniprot Name
Aldehyde oxidase
Molecular Weight
147916.735 Da
References
  1. Sugihara K, Kitamura S, Tatsumi K: Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos. 1996 Feb;24(2):199-202. [PubMed:8742231]
  2. Kitamura S, Ohashi KNK, Sugihara K, Hosokawa R, Akagawa Y, Ohta S: Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver. Biol Pharm Bull. 2001 Jul;24(7):856-9. [PubMed:11456132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:44